June 27, 2016 10:05 ET Takes a Technical Look at Innovus Pharmaceuticals' Stock Chart

REDONDO BEACH, CA--(Marketwired - Jun 27, 2016) -, a leading financial news and information portal offering free real time public company filing alerts, offers a technical evaluation of Innovus Pharmaceuticals' (OTC PINK: INNV) stock chart.

After a couple years of downtrending, shares of Innovus Pharmaceuticals (INNV) hit an all-time low at 2.8 cents in February. At that point, technicals and fundamentals collided. Bolstered by positive drug development news, the stock has rallied from the low, rising as high at 36.9 cents late in May to mark the highest point since October 2014. Across more than four months, the INNV chart has developed a strong uptrend by creating a series of higher highs and higher lows.

For a look at what might come next, click the link or copy and paste in your browser to see a full analysis on


Founded in 2004, provides free real time filing alerts to over 600,000 registered members and offers services to help public companies grow their audience of interested investors.


Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit:

Contact Information